Compare VLN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | AGEN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 126.2M |
| IPO Year | N/A | 1999 |
| Metric | VLN | AGEN |
|---|---|---|
| Price | $1.34 | $3.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 574.9K | 403.0K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.99 | $68.25 |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.30 | $1.38 |
| 52 Week High | $3.34 | $7.34 |
| Indicator | VLN | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 53.55 |
| Support Level | N/A | $2.92 |
| Resistance Level | $1.63 | $4.62 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.09 | 59.65 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).